SH2B3 and breast carcinoma: On the contrary, previous studies show that SH2B3 promotes Jak/STAT signaling in myeloproliferative neoplasms (Oh et al., 2010) and promotes ovarian cancer (Ding et al., 2015), breast cancer (Lv et al., 2020), and anaplastic thyroid carcinoma (Zhong et al., 2020) progression.